AnaptysBio, Inc. (ANAB)
64.93
-2.43
(-3.61%)
USD |
NASDAQ |
May 07, 14:29
AnaptysBio SG&A Expense (TTM) : 50.74M for Dec. 31, 2025
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Vanda Pharmaceuticals, Inc. | 237.95M |
| ADMA Biologics, Inc. | 96.42M |
| Nektar Therapeutics | 68.67M |
| Rigel Pharmaceuticals, Inc. | 88.18M |
| Axsome Therapeutics, Inc. | 449.81M |